-
STAT+: Once high-flying Rubius to shut down. Its flameout is a lesson for biotech
STAT+: Once high-flying Rubius to shut down. Its flameout is a lesson for biotech Rubius Therapeutics went public in 2018 at a $2 billion valuation — the largest biotech stock market debut at that time. On Wednesday, the company — battered down to a market value of $15 million — said it was shutting down…
-
STAT+: Reata’s ‘toss up’ drug approval decision is in the unpredictable hands of FDA’s Billy Dunn
STAT+: Reata’s ‘toss up’ drug approval decision is in the unpredictable hands of FDA’s Billy Dunn In the aftermath of the Food and Drug Administration’s Aduhelm debacle, the agency’s neuroscience chief Billy Dunn has another controversial approval decision to make. It will once again test his willingness to apply the FDA’s doctrine of “regulatory flexibility”…
-
STAT+: New results show Cassava’s Alzheimer’s drug has placebo-like efficacy
STAT+: New results show Cassava’s Alzheimer’s drug has placebo-like efficacy Cassava Sciences had long claimed that its experimental treatment for Alzheimer’s disease was capable of improving the cognition of patients — a benefit no other Alzheimer’s drug has ever shown. But mid-stage study results updated on Tuesday now show the cognitive status of patients worsening…
Got any book recommendations?